Third Arc Bio
Transformational therapies for solid tumors and immune diseases using multifunctional antibodies to precisely activate or inhibit T cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $165m | Series A | |
| Total Funding | 000k | ||
Related Content
Third Arc Bio is a biotechnology company focused on developing innovative therapies for solid tumors and immune diseases. The company specializes in creating multifunctional antibodies that form immune synapses, which are structures that allow immune cells to communicate and coordinate their actions. These antibodies are designed to precisely activate or inhibit T cells, a type of immune cell, to target and treat specific diseases.
Third Arc Bio operates in the biopharmaceutical market, primarily serving patients with cancer and immune-related conditions. The company employs a business model centered around research and development, aiming to bring new, effective treatments to market. Revenue is generated through the development and commercialization of these therapies, often in collaboration with larger pharmaceutical companies.
The company's world-class team has a proven track record of success, positioning Third Arc Bio to advance the next generation of highly innovative medicines that redefine the standard of care.
Keywords: biotechnology, solid tumors, immune diseases, multifunctional antibodies, T cells, immune synapses, cancer treatment, biopharmaceutical, innovative medicines, research and development.